Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investigation Into Cephalon’s Actiq Winding Down

This article was originally published in The Pink Sheet Daily

Executive Summary

Connecticut Attorney General’s office will meet with Cephalon next month to discuss marketing of the pain medication.

You may also be interested in...



Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths

Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.

Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths

Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.

Lilly, AstraZeneca, Cephalon Marketing Practices Under Review By House Committee

Rep. Waxman is requesting information into the marketing of Zyprexa, Seroquel, Actiq and Fentora.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel